Update on Huntington's disease: Advances in care and emerging therapeutic options

Parkinsonism and Related Disorders

Volumn 21, Issue 3, 2015, Pages 169-178

  Zielonka, Daniel ^a   Mielcarek, Michal ^b   Landwehrmeyer, G Bernhard ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Disease modifying treatment; Experimental medicine; Huntington's disease; Symptomatic relief; Therapy

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; HUNTINGTIN; MESSENGER RNA; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PRIDOPIDINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TIAPRIDE; VENLAFAXINE;

AGGRESSION; ANXIETY DISORDER; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; CELL THERAPY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; GENE; HTT GENE; HUMAN; HUNTINGTON CHOREA; IMPULSIVENESS; IRRITABILITY; MEDICATION COMPLIANCE; MOUTH HYGIENE; MOUTH PROTECTOR; NONHUMAN; NUTRITIONAL STATUS; OBSESSIVE COMPULSIVE DISORDER; OCCUPATIONAL THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); EMERGENCY TREATMENT; HUNTINGTON DISEASE; PALLIATIVE THERAPY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; EMERGENCY TREATMENT; HUMANS; HUNTINGTON DISEASE; PALLIATIVE CARE;

EID: 84923225433     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.12.013     Document Type: Review

References (129)

1. HDRG Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
2. Walker F.O. Huntington's disease. Semin Neurol 2007, 27:143-150.
3. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
4. Karadima G., Dimovasili C., Koutsis G., Vassilopoulos D., Panas M. Age at onset in Huntington's disease: replication study on the association of HAP1. Park Relat Disord 2012, 18:1027-1028.
5. Zielonka D., Marinus J., Roos R.A., De Michele G., Di Donato S., Putter H., et al. The influence of gender on phenotype and disease progression in patients with Huntington's disease. Park Relat Relat Disord 2013, 19:192-197.
6. Baxendale S., Abdulla S., Elgar G., Buck D., Berks M., Micklem G., et al. Comparative sequence analysis of the human and pufferfish Huntington's disease genes. Nat Genet 1995, 10:67-76.
7. Li S.H., Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004, 20:146-154.
8. Li S.H., Schilling G., Young W.S., Li X.J., Margolis R.L., Stine O.C., et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993, 11:985-993.
9. Strong T.V., Tagle D.A., Valdes J.M., Elmer L.W., Boehm K., Swaroop M., et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993, 5:259-265.
10. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007, 104:17204-17209.
11. Hoffner G., Kahlem P., Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. JCell Sci 2002, 115:941-948.
12. Godin J.D., Colombo K., Molina-Calavita M., Keryer G., Zala D., Charrin B.C., et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
13. Velier J., Kim M., Schwarz C., Kim T.W., Sapp E., Chase K., et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol 1998, 152:34-40.
14. Mielcarek M., Bondulich M.K., Inuabasi L., Franklin S.A., Muller T., Bates G.P. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. PloS One 2014, 9:e108961.
15. Mielcarek M., Inuabasi L., Bondulich M.K., Muller T., Osborne G.F., Franklin S.A., et al. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. PLoS Genet 2014, 10:e1004550.
16. Zielonka D., Piotrowska I., Mielcarek M. Cardiac dysfunction in Huntington's disease. Exp Clin Cardiol 2014, 20:2547-2554.
17. Zielonka D., Piotrowska I., Marcinkowski J.T., Mielcarek M. Skeletal muscle pathology in Huntington's Disease. Front Physiol 2014, 5:1-5.
18. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995, 11:155-163.
19. Zhang H., Das S., Li Q.Z., Dragatsis I., Repa J., Zeitlin S., et al. Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci 2008, 9:38.
20. O'Kusky J.R., Nasir J., Cicchetti F., Parent A., Hayden M.R. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Res 1999, 818:468-479.
21. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823.
22. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000, 26:300-306.
23. Ehrnhoefer D.E., Sutton L., Hayden M.R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neurosci 2011, 17:475-492.
24. Jeong H., Then F., Melia T.J., Mazzulli J.R., Cui L., Savas J.N., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
25. Dong G., Callegari E., Gloeckner C.J., Ueffing M., Wang H. Mass spectrometric identification of novel posttranslational modification sites in Huntingtin. Proteomics 2012, 12:2060-2064.
26. Goehler H., Lalowski M., Stelzl U., Waelter S., Stroedicke M., Worm U., et al. Aprotein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004, 15:853-865.
27. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
28. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 2008, 8:57-64.
29. Hughes R.E., Lo R.S., Davis C., Strand A.D., Neal C.L., Olson J.M., et al. Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci U S A 2001, 98:13201-13206.
30. Venuto C.S., McGarry A., Ma Q., Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012, 27:31-41.
31. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. JClin Investig 2011, 121:476-483.
32. Mielcarek M., Landles C., Weiss A., Bradaia A., Seredenina T., Inuabasi L., et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 2013, 11:e1001717.
33. Mielcarek M., Seredenina T., Stokes M.P., Osborne G.F., Landles C., Inuabasi L., et al. HDAC4 does not act as a protein deacetylase in the postnatal murine brain invivo. PloS One 2013, 8:e80849.
34. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003, 100:2041-2046.
35. Mielcarek M., Benn C.L., Franklin S.A., Smith D.L., Woodman B., Marks P.A., et al. SAHA decreases HDAC 2 and 4 levels invivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PloS One 2011, 6:e27746.
36. Scognamiglio A., Nebbioso A., Manzo F., Valente S., Mai A., Altucci L. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008, 1783:2030-2038.
37. Labbadia J., Morimoto R.I. Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 2013, 38:378-385.
38. Quaid K.A., Sims S.L., Swenson M.M., Harrison J.M., Moskowitz C., Stepanov N., et al. Living at risk: concealing risk and preserving hope in Huntington disease. JGenet Couns 2008, 17:117-128.
39. Shang H., Danek A., Landwehrmeyer B., Burgunder J.M. Huntington's disease: new aspects on phenotype and genotype. Park Relat Disord 2012, 18(Suppl.1):S107-S109.
40. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
41. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
42. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 2005, 102:5820-5825.
43. Yu D., Pendergraff H., Liu J., Kordasiewicz H.B., Cleveland D.W., Swayze E.E., et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012, 150:895-908.
44. Lombardi M.S., Jaspers L., Spronkmans C., Gellera C., Taroni F., Di Maria E., et al. Amajority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009, 217:312-319.
45. Pfister E.L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol - CB 2009, 19:774-778.
46. Sah D.W., Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. JClin Investig 2011, 121:500-507.
47. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 2008, 105:5868-5873.
48. Sinha M., Ghose J., Bhattarcharyya N.P. Micro RNA-214,-150,-146a and-125b target Huntingtin gene. RNA Biol 2011, 8:1005-1021.
49. Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.
50. Garriga-Canut M., Agustin-Pavon C., Herrmann F., Sanchez A., Dierssen M., Fillat C., et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A 2012, 109:E3136-E3145.
51. Zhang Y., Friedlander R.M. Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther 2011, 18:1139-1149.
52. Niewoehner J., Bohrmann B., Collin L., Urich E., Sade H., Maier P., et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014, 81:49-60.
53. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
54. Moffitt H., McPhail G.D., Woodman B., Hobbs C., Bates G.P. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PloS One 2009, 4:e8025.
55. Chopra V., Quinti L., Kim J., Vollor L., Narayanan K.L., Edgerly C., et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Reports 2012, 2:1492-1497.
56. Labbadia J., Cunliffe H., Weiss A., Katsyuba E., Sathasivam K., Seredenina T., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. JClin Investig 2011, 121:3306-3319.
57. Labbadia J., Novoselov S.S., Bett J.S., Weiss A., Paganetti P., Bates G.P., et al. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 2012, 135:1180-1196.
58. Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A 2002, 99(Suppl.4):16400-16406.
59. Landwehrmeyer G.B., Dubois B., de Yebenes J.G., Kremer B., Gaus W., Kraus P.H., et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007, 62:262-272.
60. Armstrong M.J., Miyasaki J.M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012, 79:597-603.
61. Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord 2013, 28:1030-1033.
62. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009, CD006456.
63. Burgunder J.M., Guttman M., Perlman S., Goodman N., van Kammen D.P., Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr 2011, 3:RRN1260.
64. Suchowersky O., Armstrong M.J., Miyasaki J. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013, 80:970.
65. Huntington Study G. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
66. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002, 59:694-699.
67. O'Suilleabhain P., Dewey R.B. Arandomized trial of amantadine in Huntington disease. Arch Neurol 2003, 60:996-998.
68. Lucetti C., Del Dotto P., Gambaccini G., Dell' Agnello G., Bernardini S., Rossi G., et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003, 60:1995-1997.
69. Lucetti C., Gambaccini G., Bernardini S., Dell'Agnello G., Petrozzi L., Rossi G., et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci - Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2002, 23(Suppl.2):S83-S84.
70. Heckmann J.M., Legg P., Sklar D., Fine J., Bryer A., Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004, 63:597-598.
71. Fekete R., Davidson A., Ondo W.G., Cohen H.S. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Park Relat Disord 2012, 18:896-898.
72. Dyhring T., Nielsen E.O., Sonesson C., Pettersson F., Karlsson J., Svensson P., et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010, 628:19-26.
73. Ponten H., Kullingsjo J., Lagerkvist S., Martin P., Pettersson F., Sonesson C., et al. Invivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010, 644:88-95.
74. Rung J.P., Carlsson A., Markinhuhta K.R., Carlsson M.L. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuro Psychopharmacol Biol Psychiatry 2005, 29:833-839.
75. Tedroff J., Torstenson R., Hartvig P., Sonesson C., Waters N., Carlsson A., et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 1998, 28:280-287.
76. Natesan S., Svensson K.A., Reckless G.E., Nobrega J.N., Barlow K.B., Johansson A.M., et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high invivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. JPharmacol Exp Ther 2006, 318:810-818.
77. Seeman P., Tokita K., Matsumoto M., Matsuo A., Sasamata M., Miyata K. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse 2009, 63:930-934.
78. Rung J.P., Rung E., Helgeson L., Johansson A.M., Svensson K., Carlsson A., et al. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. JNeural Transm 2008, 115:899-908.
79. Kara E., Lin H., Svensson K., Johansson A.M., Strange P.G. Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 2010, 161:1343-1350.
80. Sahlholm K., Arhem P., Fuxe K., Marcellino D. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry 2013, 18:12-14.
81. Lundin A., Dietrichs E., Haghighi S., Goller M.L., Heiberg A., Loutfi G., et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) inpatients with Huntington's disease. Clin Neuropharmacol 2010, 33:260-264.
82. Huntington Study Group HI Arandomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013, 28:1407-1415.
83. Reilmann R. The pridopidine paradox in Huntington's disease. Mov Disord - Off J Mov Disord Soc 2013, 28:1321-1324.
84. Groves M., van Duijn E., Anderson K., Craufurd D., Edmondson M.C., Goodman N., et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr 2011, 3:RRN1259.
85. Anderson K., Craufurd D., Edmondson M.C., Goodman N., Groves M., van Duijn E., et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease. PLoS Curr 2011, 3:RRN1261.
86. van Duijn E., Kingma E.M., van der Mast R.C. Psychopathology in verified Huntington's disease gene carriers. JNeuropsychiatry Clin Neurosci 2007, 19:441-448.
87. Epping E.A., Paulsen J.S. Depression in the early stages of Huntington disease. Neurodegener Dis Manag 2011, 1:407-414.
88. Paulsen J.S., Nehl C., Hoth K.F., Kanz J.E., Benjamin M., Conybeare R., et al. Depression and stages of Huntington's disease. JNeuropsychiatry Clin Neurosci 2005, 17:496-502.
89. Holl A.K., Wilkinson L., Painold A., Holl E.M., Bonelli R.M. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010, 25:46-50.
90. Paulsen J.S., Hoth K.F., Nehl C., Stierman L. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005, 162:725-731.
91. Peschanski M., Cesaro P., Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995, 68:273-285.
92. Palfi S., Conde F., Riche D., Brouillet E., Dautry C., Mittoux V., et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998, 4:963-966.
93. Kendall A.L., Rayment F.D., Torres E.M., Baker H.F., Ridley R.M., Dunnett S.B. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998, 4:727-729.
94. Dunnett S.B., Rosser A.E. Stem cell transplantation for Huntington's disease. Exp Neurol 2007, 203:279-292.
95. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
96. Cicchetti F., Saporta S., Hauser R.A., Parent M., Saint-Pierre M., Sanberg P.R., et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009, 106:12483-12488.
97. Gallina P., Paganini M., Lombardini L., Mascalchi M., Porfirio B., Gadda D., et al. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010, 222:30-41.
98. Madrazo I., Cuevas C., Castrejon H., Guizar-Sahagun G., Franco-Bourland R.E., Ostrosky-Solis F., et al. The first homotopic fetal homograft of the striatum in the treatment of Huntington's disease. Gac Medi Mex 1993, 129:109-117.
99. Kopyov O.V., Jacques S., Lieberman A., Duma C.M., Eagle K.S. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998, 149:97-108.
100. Pundt L.L., Kondoh T., Conrad J.A., Low W.C. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res Bull 1996, 39:23-32.
101. Wictorin K., Ouimet C.C., Bjorklund A. Intrinsic organization and connectivity of intrastriatal striatal transplants in rats as revealed by DARPP-32 immunohistochemistry: specificity of connections with the lesioned host brain. Eur J Neurosci 1989, 1:690-701.
102. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
103. Bachoud-Levi A.C., Gaura V., Brugieres P., Lefaucheur J.P., Boisse M.F., Maison P., et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006, 5:303-309.
104. Hauser R.A., Furtado S., Cimino C.R., Delgado H., Eichler S., Schwartz S., et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002, 58:687-695.
105. Furtado S., Sossi V., Hauser R.A., Samii A., Schulzer M., Murphy C.B., et al. Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol 2005, 58:331-337.
106. Cicchetti F., Soulet D., Freeman T.B. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain - J Neurol 2011, 134:641-652.
107. Rosser A.E., Barker R.A., Harrower T., Watts C., Farrington M., Ho A.K., et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. JNeurol Neurosurg Psychiatry 2002, 73:678-685.
108. Barker R.A., Mason S.L., Harrower T.P., Swain R.A., Ho A.K., Sahakian B.J., et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. JNeurol Neurosurg Psychiatry 2013, 84:657-665.
109. Reuter I., Tai Y.F., Pavese N., Chaudhuri K.R., Mason S., Polkey C.E., et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. JNeurol Neurosurg Psychiatry 2008, 79:948-951.
110. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013, 12:637-649.
111. Cubo E., Shannon K.M., Penn R.D., Kroin J.S. Internal globus pallidotomy in dystonia secondary to Huntington's disease. Mov Disord - Off J Mov Disord Soc 2000, 15:1248-1251.
112. Watarai M., Hashimoto T., Yamamoto K., Matsumoto Y., Tada T., Ikeda S. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology 2003, 61:1452-1454.
113. Spiegel E.A., Wycis H.T. Pallidothalamotomy in chorea. Arch Neurol Psychiatry 1950, 64:295-296.
114. Moro E., Lang A.E., Strafella A.P., Poon Y.Y., Arango P.M., Dagher A., et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004, 56:290-294.
115. Ruge D., Tisch S., Hariz M.I., Zrinzo L., Bhatia K.P., Quinn N.P., et al. Deep brain stimulation effects in dystonia: time course of electrophysiological changes in early treatment. Mov Disord - Off J Mov Disord Soc 2011, 26:1913-1921.
116. Spielberger S., Hotter A., Wolf E., Eisner W., Muller J., Poewe W., et al. Deep brain stimulation in Huntington's disease: a 4-year follow-up case report. Mov Disord - Off J Mov Disord Soc 2012, 27:806-807. author reply 7-8.
117. Lopez-Sendon Moreno J.L., Garcia-Caldentey J., Regidor I., del Alamo M., Garcia de Yebenes J. A5-year follow-up of deep brain stimulation in Huntington's disease. Park Relat Disord 2014, 20:260-261.
118. Garcia-Ruiz P.J., Ayerbe J., del Val J., Herranz A. Deep brain stimulation in disabling involuntary vocalization associated with Huntington's disease. Park Relat Disord 2012, 18:803-804.
119. Skirton H., Williams J.K., Jackson Barnette J., Paulsen J.S. Huntington disease: families' experiences of healthcare services. JAdv Nurs 2010, 66:500-510.
120. Veenhuizen R.B., Tibben A. Coordinated multidisciplinary care for Huntington's disease. An outpatient department. Brain Res Bull 2009, 80:192-195.
121. Nance M.A. Comprehensive care in Huntington's disease: a physician's perspective. Brain Res Bull 2007, 72:175-178.
122. Quinn L. Physiotherapy clinical guidelines for Huntington's disease. Neurodegen Dis Manage 2012, 2(1):21-31.
123. Brotherton A., Rowell A., Zoia V., Simpson S.A., Rae D. Nutritional management of individuals with Huntington's disease: nutritional guidelines. Neurodegen Dis Manage 2012, 2(1):33-43.
124. Hamilton A., Loucas M., Twiston-Davies R., Matheson K.Y., Simpson S.A., Rae D. Oral feeding in Huntington's disease: a guideline document for speech and language therapists. Neurodegen Dis Manage 2012, 2(1):45-53.
125. Hamilton A., Heemskerk A., Twiston-Davies R., Matheson K.Y., Simpson S.A., Rae D. Management of speech, language and communication difficulties in Huntington's disease. Neurodegen Dis Manage 2012, 2(1):76-77.
126. Manley G., Carlsson A., Ahlborg B., Martensson A., Nilsson M.B., Simpson S.A., et al. Guideline for oral healthcare of adults with Huntington's disease. Neurodegen Dis Manage 2012, 2(1):55-65.
127. Cook C., Wagstaff A., Simpson S.A., Rae D. Development of guidelines for occupational therapy in Huntington's disease. Neurodegen Dis Manage 2012, 2(1):79-87.
128. Mestre T.A., Ferreira J.J. An evidence-based approach in the treatment of Huntington's disease. Park Relat Disord 2012, 18:316-320.
129. Marcinkowski J.T., Zielonka D. Hope in Huntington's disease. A survey in counselling patients with Huntington's disease, as well as the caregivers. Neural Regen Res 2009, 4:717-720.